Speaker Profile

Pharm.D., Associate Professor, University of Florida

Rhonda M. Cooper-DeHoff, Pharm.D., M.S., is a graduate of the University of California, San Francisco School of Pharmacy. Dr. Cooper-DeHoff’s area of research interest include hypertension and cardiovascular disease pharmacogenetics, as well as the factors that influence outcomes with antihypertensive and cardiovascular treatments. She also has interest in the area of antihypertensive drug use and adverse metabolic effects including diabetes, as well as the area of dietary supplements. In total, she has over 200 publications and many have been of high impact, helping to define demographic, clinical, metabolic, metabolomic and genetic and pharmacogenetic factors associated with responses to antihypertensive drugs and cardiovascular outcomes with antihypertensive therapy. She is currently conducting research in the area of ‘big data’ science including the use of EHR data from multiple health systems to conduct real world longitudinal surveillance of important blood pressure control and process metrics, as well as preemptive pharmacogenetics testing in multiple therapeutic areas.

Tracking BP Control Performance and Process Metrics in 25 US Health Systems
BP control (<140/90 mmHg), calculated using real-world data from 25 health systems across the US, averaged 62%, and there was substantial variation by health system (range 44%-74%). A new class of antihypertensive medication was prescribed in only 12% (range 0.6%-25%) of patient visits where BP was uncontrolled BP. When a medication intensification event occurred, subsequent SBP was 15 ± 20 mm Hg lower on average (range 5-18 mm Hg). Major opportunities exist for improving BP control and reducing disparities.

 Session Abstract – PMWC 2022 Silicon Valley

Track Chair:
Keith Yamamoto, UCSF

Patient-centric data – Real-World Evidence (RWE) and Real-World Data (RWD) - is becoming instrumental in the drug development process and for health care decisions in general. This data is not only informative for the process from discovery to new indications, clinical trial design, and drug development, it also can be of value to monitor post-marketing drug safety and for decision support in clinical practice. As the data becomes a decision driver, science companies and medical organizations are increasingly focused on leveraging RWD and RWE to not only better understand the patient populations using their drugs and the respective outcomes, but also to accelerate clinical decision support. This session will focus on the various aspects of integrating RWE and RWD to support drug development and clinical decision support


  • Realizing the Promise of Precision Medicine Using Real-world Evidence
    Session Chair: Atul Butte, UCSF
    - James Wall, Stanford
    - Nancy A. Dreyer, IQVIA
    - Mark Laabs, RCRF
    - John Concato, FDA
    - Rhonda Cooper-DeHoff, University of Florida
  • Opportunities and Challenges in Using Real World Data (RWD)
    Session Chair: Vivek Rudrapatna, UCSF
    - Kathy Giacomini, UCSF
  • How Are Patient Data Revolutionizing Precision Medicine?
    Session Chair: Clara Lajonchere, UCLA
    - Sharon Terry, Genetic Alliance
    - Farid Vij ,Ciitizen
    - Latha Palaniappan, Stanford
  • Regulatory Requirements and Challenges for Using RWE
    Session Chair: Sheila Walcoff, Goldbug Strategies
  • Government Partnerships: California Initiative to Advance Precision Medicine
    Session Chair: Julianne McCall, California Initiative to Advance Precision Medicine
    - Pablo Tamayo, UCSD
    - George M. Slavich, UCLA
  • Leveraging RWE to Create Value
    Session Chair: Kathryn A. Phillips, UCSF
    - Phil Febbo, Illumina
    - Suzanne Belinson, Tempus
    - Patricia Deverka, UCSF
    - Stacey Dacosta Byfield, OptumLabs
  • The Past, Present, and Future of RWE
    Session Chair: Keith Yamamoto, UCSF
    - Matthew Porteus, Stanford